Main roads
-
The acting head of the National Institute of Allergy and Infectious Diseases has resigned from his position
-
The reason for his departure is not clear
-
Health officials worry that as the U.S. grapples with the Ebola outbreak and hantavirus concerns, the change in leadership is not timely.
FRIDAY, MAY 22, 2026 (News of Health Day) — Dr. Jeffrey Taubenbergerwho served as acting director of the National Institute of Allergy and Infectious Diseases (NIAID) for just over a year, has resigned for undisclosed reasons.
While Senator Tammy Baldwina Wisconsin Democrat, revealed the news during a Senate Appropriations Committee hearing on Thursday, according to the news service, his withdrawal came about two weeks ago. STAT. Taubenberger, who has been in the role since April 2025, did not respond STAT asking about his condition.
According to him, it is not known whether he voluntarily resigned or was asked to do so STAT.
According to the NIAID website, it evaluates treatment and prevention options for a number of diseases and conditions. This includes what research will be funded and what vaccines will be developed in the future. It is under the umbrella of the National Institutes of Health (NIH) under the US Department of Health and Human Services.
At a time of global disease outbreaks and fears of another pandemic, the leadership shakeup at NIAID has officials worried.
In Baldwin’s opening remarks at the meeting, he noted that “other senior NIAID officials have also reportedly been reassigned and forced out of their positions in the midst of the Ebola outbreak. We have a leadership vacuum at the world’s top infectious disease institute, and across our health care institutions, that is a huge concern.”
The news of Taubenberger’s departure follows the news of three other heads of the institute. Among them were two senior officials who manage NIAID’s grant portfolio. They were reassigned to the National Institute on Minority Health and Health Disparities. Meanwhile, the head of the Department of Allergy, Immunology and Transplantation was offered a transfer to the director’s office. STAT.
In response to the question of Senator Patty Murraya Democrat from Washington state, director of the NIH Dr. Jay Bhattacharyaattributed these moves to a change in focus.
“We’ve shifted NIAID’s focus to addressing diseases and conditions that people actually have, including hantavirus, including Ebola, and more,” he said. “This change means we need new leadership. The people you’re talking about are still at NIH, but they’ve been assigned to places where they can help NIAID’s changed missions to focus on infectious diseases and allergy and immunology.”
According to Bhattacharya, he did not immediately deny or deny Baldwin’s claim that Taubenberger would no longer serve as director of NIAID. STAT.
Currently, NIAID still lacks a permanent director, which could affect its ability to plan long-term projects or establish initiatives for the broader research community.
More information
The National Institute of Allergy and Infectious Diseases has more information role in research.
SOURCE: STATE, May 21, 2026
What does this mean for you?
Changes in leadership can affect what is prioritized (or prioritized) for public health.
